Results from Eli Lilly’s TRAILBLAZER-ALZ 2 Randomized Clinical Trial looking at the use of donanemab in early symptomatic Alzheimer’s disease … read more
By Fiona Fox This blog contains the thoughts of the author rather than representing the work or policy of the … read more
A press release from Eli Lilly states that their antibody treatment, donanemab, significantly slowed cognitive and functional decline in phase … read more
A conference abstract (not a published paper) presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2022 compares the … read more
Results of the phase 3 trial of lecanemab for early Alzheimer’s disease has been published in New England Journal of … read more
The U.S. Food & Drug Administration (FDA) has today approved aducanumab (Aduhelm) to treat patients with Alzheimer’s disease. Prof … read more